‘We remain focused on providing patients with access to Ingrezza and preparing for the approval of opicapone in the U.S…’said Neurocrine CEO Kevin Gorman. Photo by Jamie Scott Lytle.

‘We remain focused on providing patients with access to Ingrezza and preparing for the approval of opicapone in the U.S…’said Neurocrine CEO Kevin Gorman. Photo by Jamie Scott Lytle.

Neurocrine Biosciences reported revenue of $222...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129